WO2009033489A3 - Selective pacl inhibitors for use in the treatment of migraine and headaches - Google Patents
Selective pacl inhibitors for use in the treatment of migraine and headaches Download PDFInfo
- Publication number
- WO2009033489A3 WO2009033489A3 PCT/DK2008/050223 DK2008050223W WO2009033489A3 WO 2009033489 A3 WO2009033489 A3 WO 2009033489A3 DK 2008050223 W DK2008050223 W DK 2008050223W WO 2009033489 A3 WO2009033489 A3 WO 2009033489A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- migraine
- inhibitors
- treatment
- selective
- pacl
- Prior art date
Links
- 206010019233 Headaches Diseases 0.000 title abstract 2
- 208000019695 Migraine disease Diseases 0.000 title abstract 2
- 231100000869 headache Toxicity 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 206010027599 migraine Diseases 0.000 title abstract 2
- YQNRVGJCPCNMKT-JLPGSUDCSA-N 2-(4-benzylpiperazin-1-yl)-n-[(2-hydroxy-3-prop-2-enyl-phenyl)methylideneamino]acetamide Chemical compound OC1=C(CC=C)C=CC=C1\C=N/NC(=O)CN1CCN(CC=2C=CC=CC=2)CC1 YQNRVGJCPCNMKT-JLPGSUDCSA-N 0.000 abstract 1
- 101001139126 Homo sapiens Krueppel-like factor 6 Proteins 0.000 abstract 1
- 101001133600 Homo sapiens Pituitary adenylate cyclase-activating polypeptide type I receptor Proteins 0.000 abstract 1
- 101001080401 Homo sapiens Proteasome assembly chaperone 1 Proteins 0.000 abstract 1
- 102100020679 Krueppel-like factor 6 Human genes 0.000 abstract 1
- 229960005552 PAC-1 Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Vascular Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Abstract
The present invention relates to the use of selective PAC1 inhibitors in the manufacture of a medicament for the treatment of migraine or headache.
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA200701313 | 2007-09-11 | ||
DKPA200701313 | 2007-09-11 | ||
DKPA200800469 | 2008-03-31 | ||
DKPA200800469 | 2008-03-31 | ||
US5714808P | 2008-05-29 | 2008-05-29 | |
US60/057,148 | 2008-05-29 | ||
DKPA200801180 | 2008-08-28 | ||
DKPA200801180 | 2008-08-28 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2009033489A2 WO2009033489A2 (en) | 2009-03-19 |
WO2009033489A3 true WO2009033489A3 (en) | 2009-05-07 |
Family
ID=40263329
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/DK2008/050223 WO2009033489A2 (en) | 2007-09-11 | 2008-09-11 | Selective pacl inhibitors for use in the treatment of migraine and headaches |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2009033489A2 (en) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014144632A2 (en) | 2013-03-15 | 2014-09-18 | Amgen Inc. | Human pac1 antibodies |
US9700549B2 (en) | 2013-10-03 | 2017-07-11 | David Wise | Compositions and methods for treating pelvic pain and other conditions |
JP6956631B2 (en) | 2014-09-15 | 2021-11-02 | アムジェン インコーポレイテッド | Bispecific anti-CGRP receptor / PAC1 receptor antigen-binding protein and its use |
JP6924148B2 (en) | 2015-04-16 | 2021-08-25 | ハー・ルンドベック・アクチエゼルスカベット | Anti-PACAP antibodies and their use |
US10822408B2 (en) | 2015-12-15 | 2020-11-03 | Amgen Inc. | PACAP antibodies and uses thereof |
SG11201808630WA (en) | 2016-04-15 | 2018-10-30 | Alder Biopharmaceuticals Inc | Humanized anti-pacap antibodies and uses thereof |
AR111842A1 (en) | 2017-06-02 | 2019-08-21 | Amgen Inc | PAC1 PEPTIDE ANTAGONISTS |
UY38050A (en) | 2018-01-12 | 2019-07-31 | Amgen Inc | PAC1 ANTIBODIES AND THEIR USES CROSSED REFERENCE TO RELATED APPLICATIONS |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997040388A1 (en) * | 1996-04-25 | 1997-10-30 | Shiseido Company, Ltd. | Peptides having specific affinity to pacap type 1 receptors |
WO2002033103A2 (en) * | 2000-10-16 | 2002-04-25 | Deutsches Krebsforschungszentrum | Non-human mammal with modified pacap type i receptor |
US20020182729A1 (en) * | 2001-01-11 | 2002-12-05 | Dicicco-Bloom Emanuel | Pituitary adenylate cyclase-activating polypeptide (PACAP) is an anti-mitogenic signal for selected neuronal precursors in vivo |
US20050129687A1 (en) * | 2003-11-03 | 2005-06-16 | University Of Vermont And State Agricultural College | Use of inhibitors of PACAP receptor activity for treatment of overactive bladder and pelvic floor pain syndrome |
US20070054843A1 (en) * | 2005-08-26 | 2007-03-08 | Yeomans David C | Methods for treatment of headaches by administration of oxytocin |
CN101125881A (en) * | 2007-07-20 | 2008-02-20 | 暨南大学 | Recombinant PAC1 receptor antagonist D(25-44)RMMAX and its expression method and application |
-
2008
- 2008-09-11 WO PCT/DK2008/050223 patent/WO2009033489A2/en active Application Filing
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997040388A1 (en) * | 1996-04-25 | 1997-10-30 | Shiseido Company, Ltd. | Peptides having specific affinity to pacap type 1 receptors |
WO2002033103A2 (en) * | 2000-10-16 | 2002-04-25 | Deutsches Krebsforschungszentrum | Non-human mammal with modified pacap type i receptor |
US20020182729A1 (en) * | 2001-01-11 | 2002-12-05 | Dicicco-Bloom Emanuel | Pituitary adenylate cyclase-activating polypeptide (PACAP) is an anti-mitogenic signal for selected neuronal precursors in vivo |
US20050129687A1 (en) * | 2003-11-03 | 2005-06-16 | University Of Vermont And State Agricultural College | Use of inhibitors of PACAP receptor activity for treatment of overactive bladder and pelvic floor pain syndrome |
US20070054843A1 (en) * | 2005-08-26 | 2007-03-08 | Yeomans David C | Methods for treatment of headaches by administration of oxytocin |
CN101125881A (en) * | 2007-07-20 | 2008-02-20 | 暨南大学 | Recombinant PAC1 receptor antagonist D(25-44)RMMAX and its expression method and application |
Non-Patent Citations (4)
Title |
---|
BEEBE ET AL: "Discovery and SAR of hydrazide antagonists of the pituitary adenylate cyclase-activating polypeptide (PACAP) receptor type 1 (PAC1-R)", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, ELSEVIER SCIENCE, GB, vol. 18, no. 6, 18 January 2008 (2008-01-18), pages 2162 - 2166, XP022526351, ISSN: 0960-894X * |
BIRK ET AL: "The effect of intravenous PACAP38 on cerebral hemodynamics in healthy volunteers", REGULATORY PEPTIDES, ELSEVIER SCIENCE BV, NL, vol. 140, no. 3, 28 March 2007 (2007-03-28), pages 185 - 191, XP005928170, ISSN: 0167-0115 * |
JONGSMA H ET AL: "MARKEDLY REDUCED CHRONIC NOCICEPTIVE RESPONSE IN MICE LACKING THE PAC1 RECEPTOR", NEUROREPORT, LIPPINCOTT WILLIAMS & WILKINS, US, vol. 12, no. 10, 20 July 2001 (2001-07-20), pages 2215 - 2219, XP001071197, ISSN: 0959-4965 * |
MORO OSAMU ET AL: "Functional characterization of structural alterations in the sequence of the vasodilatory peptide maxadilan yields a pituitary adenylate cyclase-activating peptide type 1 receptor-specific antagonist", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 274, no. 33, 13 August 1999 (1999-08-13), pages 23103 - 23110, XP002514471, ISSN: 0021-9258 * |
Also Published As
Publication number | Publication date |
---|---|
WO2009033489A2 (en) | 2009-03-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2009033489A3 (en) | Selective pacl inhibitors for use in the treatment of migraine and headaches | |
EP2068798A4 (en) | Methods, compositions and apparatuses to treat wounds with pressures altered from atmospheric | |
IL223128A (en) | Use of sgc stimulators, sgc activators. alone and in combinations with pde5 inhibitors for the treatment of systemic sclerosis (ssc) | |
WO2009089494A3 (en) | Pharmaceutical compositions | |
ZA201004091B (en) | Peptidyl nitriles and uses thereof as dipeptidyl peptidase i inhibitors | |
IL206098A0 (en) | Agglomerated zeolitic absorbents, method of preparing them and uses thereof | |
HK1162352A1 (en) | Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof -3- | |
WO2010132882A3 (en) | Sublingual dexmedetomidine compositions and methods of use thereof | |
EP2337535A4 (en) | Systems, devices and methods for the treatment of tinnitus | |
IL206099A0 (en) | Agglomerated zeolitic absorbents, method of preparing them and uses thereof | |
MX2023010206A (en) | Plasma kallikrein inhibitors and uses thereof for preventing hereditary angioedema attack. | |
WO2009111310A3 (en) | Treating cleft palate | |
EP2041475A4 (en) | Method and system for delivering gas to consumers, and use thereof | |
WO2010033392A3 (en) | Methods and kits for treating cluster headache disorders | |
IL207127A0 (en) | Aldh-2 inhibitors in the treatment of addiction | |
GB2465814B (en) | Method,composition and device for the treatment of enzymes and saccharides disorders | |
WO2009158646A8 (en) | Therapeutic compounds and related methods of use | |
WO2009044153A3 (en) | Inhibitors and uses | |
HK1149012A1 (en) | Triazolium salts as par1 inhibitors, production thereof, and use as medicaments | |
HK1148956A1 (en) | Imidazopyridazines as par1 inhibitors, production thereof, and use thereof as medicaments | |
TN2011000214A1 (en) | Combination of hsp90 and herceptin inhibitors | |
EP3449917A3 (en) | Tapentadol for preventing chronification of pain | |
ZA201004467B (en) | Triazolopyridazines as pari inhibitors,production thereof,and use as medicaments | |
GB0821501D0 (en) | Method, composition, and device, for the treatment of enzymes and saccharides disorder | |
GB2457965B8 (en) | Methods and systems for determining efficacy of medicaments. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08801399 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 08801399 Country of ref document: EP Kind code of ref document: A2 |